Diabetes Metab J.  2021 Nov;45(6):866-867. 10.4093/dmj.2021.0272.

The Role of Carnitine Orotate Complex in Fatty Liver

• Yi HS

• KMID: 2522725
• DOI: http://doi.org/10.4093/dmj.2021.0272

Reference

1. Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016; 1863:2422–35.

2. Schrader M, Costello J, Godinho LF, Islinger M. Peroxisome-mitochondria interplay and disease. J Inherit Metab Dis. 2015; 38:681–702.

3. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A. 2002; 99:1870–5.

4. Pastorino JG, Snyder JW, Serroni A, Hoek JB, Farber JL. Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition. J Biol Chem. 1993; 268:13791–8.

5. Loffler M, Carrey EA, Zameitat E. Orotate (orotic acid): an essential and versatile molecule. Nucleosides Nucleotides Nucleic Acids. 2016; 35:566–77.

6. Evans DR, Guy HI. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J Biol Chem. 2004; 279:33035–8.

7. Brosnan ME, Brosnan JT. Orotic acid excretion and arginine metabolism. J Nutr. 2007; 137(6 Suppl 2):1656S–61S.

8. Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). Int J Cardiol. 2009; 134:145–7.

9. Vilskersts R, Liepinsh E, Kuka J, Cirule H, Veveris M, Kalvinsh I, et al. Myocardial infarct size-limiting and anti-arrhythmic effects of mildronate orotate in the rat heart. Cardiovasc Drugs Ther. 2009; 23:281–8.

10. Hong JH, Lee MK. Carnitine orotate complex ameliorates insulin resistance and hepatic steatosis through carnitine acetyltransferase pathway. Diabetes Metab J. 2021; 45:933–47.

11. Bae JC, Lee WY, Yoon KH, Park JY, Son HS, Han KA, et al. Improvement of nonalcoholic fatty liver disease with carnitineorotate complex in type 2 diabetes (CORONA): a randomized controlled trial. Diabetes Care. 2015; 38:1245–52.

12. Yi HS, Jeong WI. Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend? J Gastroenterol Hepatol. 2021; 28 Suppl 1:99–104.

13. Yi HS, Eun HS, Lee YS, Jung JY, Park SH, Park KG, et al. Treatment with 4-methylpyrazole modulated stellate cells and natural killer cells and ameliorated liver fibrosis in mice. PLoS One. 2015; 10:e0127946.

14. Yi HS, Lee YS, Byun JS, Seo W, Jeong JM, Park O, et al. Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice. Hepatology. 2014; 60:1044–53.

15. Moon JS, Goeminne L, Kim JT, Tian JW, Kim SH, Nga HT, et al. Growth differentiation factor 15 protects against the agingmediated systemic inflammatory response in humans and mice. Aging Cell. 2020; 19:e13195.

16. Yi HS. Implications of mitochondrial unfolded protein response and mitokines: a perspective on fatty liver diseases. Endocrinol Metab (Seoul). 2019; 34:39–46.

17. Chung HK, Kim JT, Kim HW, Kwon M, Kim SY, Shong M, et al. GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury. Sci Rep. 2017; 7:17238.